N@N

CVS, UNM, HEW, VRX, RIGL, TECH Expected To Be Higher After Earnings Releases on Tuesday

^{Published on 2009-07-29 09:30:19, Last Modified on 2010-12-22 14:38:14 - WOPRAI}
 

July 29, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, August 4th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and August earnings reports. CVS Caremark (NYSE: CVS), Unum Group (NYSE: UNM), Hewitt Associates (NYSE: HEW), Valeant Pharmaceuticals (NYSE: VRX), Rigel Pharmaceuticals (NASDAQ: RIGL) and Techne Corp (NASDAQ: TECH) are all expected to be higher after their earnings are released Tuesday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go higher after earnings are released Tuesday:

Symbol Company # of Reports Quarter Release Time

CVS CVS/Caremark Corp 12 quarters Q2 Before

UNM Unum Group 12 quarters Q2 After

HEW Hewitt Associates Inc 12 quarters Q3 Before

VRX Valeant Pharmaceuticals August earnings Q2 Before

RIGL Rigel Pharmaceuticals August earnings Q2 Before

TECH Techne Corporation August earnings Q4 Before

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

CVS Caremark Corporation (NYSE: CVS), a pharmacy services company, provides prescriptions and related healthcare services in the United States. The company operates through two segments, Pharmacy Services and Retail Pharmacy. The Pharmacy Service segment provides a range of prescription benefit management services, including mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management, and claims processing. This segment serves primarily employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals. As of December 31, 2008, the Pharmacy Services segment operated 58 retail specialty pharmacy stores, 19 specialty mail order pharmacies, and 7 mail service pharmacies located in 26 states of the United States, Puerto Rico, and the District of Columbia. The Retail Pharmacy Segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its pharmacy retail stores, and online. This segment also provides health care services. As of December 31, 2008, this segment operated 6,923 retail drugstores located in 41 states and the District of Columbia; and 560 retail health care clinics in 27 states. The company was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

Unum Group (NYSE: UNM), together with its subsidiaries, provides group and individual disability insurance products in the United States and the United Kingdom. The company also provides a portfolio of other insurance products, including long-term care insurance, life insurance, employer and employee-paid group benefits, and related services. It offers group long-term and short-term disability; group life and accidental death, and dismemberment; individual disability; group and individual long-term care; voluntary benefits; group and individual life; accident, sickness, and disability; and cancer and critical illness insurance products. The company also provides individual life and corporate-owned life insurance, reinsurance pools and management operations, group pension, health insurance, and individual annuities, as well as offers brokerage voluntary benefits. It markets its products primarily to employers interested in providing benefits to their employees. The company was formerly known as UnumProvident Corporation and changed its name to Unum Group in February 2007. Unum Group was founded in 1848 and is based in Chattanooga, Tennessee.

Hewitt Associates, Inc. (NYSE: HEW) provides human resource benefits, outsourcing, and consulting services primarily in the United States and the United Kingdom. The company operates through three segments: Benefits Outsourcing, Human Resource Business Process Outsourcing (HR BPO), and Consulting. The Benefits Outsourcing segment offers health and welfare plan administration, defined contribution plan administration, and defined benefit plan administration services. The HR BPO segment provides talent management services, which include recruiting, learning and development, performance management, and succession planning; workforce management services that comprise compensation administration, total rewards, workforce administration, domestic relocation, leave management, and mobility; and core process management services, which include payroll services, benefits services, and payments services. The Consulting segment provides benefits consulting services, including retirement and financial management consulting, and health care consulting; and talent and organization consulting services. It provides an array of consulting and actuarial services covering the design, implementation, communication and operation of health and welfare, compensation, and retirement plans, as well as human resources programs and processes. Hewitt Associates was founded in 1940 and is based in Lincolnshire, Illinois.

Valeant Pharmaceuticals International (NYSE: VRX), a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers specialty pharmaceutical and over-the-counter (OTC) products in the areas of dermatology and neurology therapeutic classes. The companya�s products include Efudex/Efudix for the treatment of multiple actinic or solar keratoses and superficial basal cell carcinoma; Diastat/Diastat AcuDial, which are gel formulations of diazepam; Cesamet, a synthetic cannabinoid used for the management of severe nausea and vomiting; Bedoyecta, a brand of vitamin B complex; Bisocard to treat hypertension and angina pectoris; and Kinerase, a range of OTC and prescription cosmetic products. It also offers Mestinon, an orally active cholinesterase inhibitor used in the treatment of myasthenia gravis; M.V.I., a hospital dietary supplement used in treating trauma and burns; Migranal, a nasal spray formulation for the treatment of acute migraine headaches; Nyal to treat cough, cold, flu, sinus, and hayfever symptoms; and Virazole for the treatment of hospitalized infants and young children with lower respiratory tract infections. As of December 31, 2008, its product portfolio comprised approximately 389 products, with approximately 982 stock keeping units. The company markets its pharmaceutical products to physicians, hospitals, pharmacies, and wholesalers through its sales force, as well as through wholesalers in the United States, Mexico, Poland, and Canada. It has a collaboration agreement with Glaxo Group Limited to develop and commercialize retigabine, a neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures. Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California.

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. The companya�s products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono. The company was founded in 1996 and is based in South San Francisco, California.

TECHNE Corporation (NASDAQ: TECH) and its subsidiaries engage in the development and manufacture of biotechnology products, and hematology calibrators and controls primarily in the United States and Europe. The companya�s biotechnology product line includes Cytokines, extracted from natural sources or produced using recombinant DNA technology; Enzymes and related factors including enzyme substrates and inhibitors; antibodies, proteins produced by the immune system of an animal; assay kits, such as human and animal Quantikine kits, which allow research scientists to quantify the amount of a specific analyte; clinical diagnostic kits, including erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays; flow cytometry products consisting of fluorochrome labeled antibodies and Fluorokine kits, which measure the presence or absence of cell surface receptors for specific cytokines by flow cytometry; and intracellular cell signaling products, including antibodies, phospho-specific antibodies, antibody protein arrays, active caspases, kinases, phosphatases, and ELISA assays. The hematology product line comprises whole blood CBC controls/calibrators; linearity and reportable range controls that provide a means of assessing the linearity of hematology analyzers for white blood cells, red blood cells, platelets, and reticulocytes; whole blood reticulocyte controls for manual and automated counting of reticulocytes; whole blood flow cytometry controls for flow cytometry instruments; whole blood glucose/hemoglobin control to monitor instruments which measure glucose and hemoglobin in whole blood; erythrocyte sedimentation rate control to monitor erythrocyte sedimentation rate tests; and multi-purpose platelet reference controls for use by automated and semi-automated analyzers. TECHNE Corporation sells its products to research and clinical diagnostics markets. The company was founded in 1976 and is based in Minneapolis, Minnesota.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

One example from the SqueezeTrigger database is approximately 2.6 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering!

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641